Frailty Outweighs Polypharmacy

Angie Szumlinski News

A study was done to investigate the association between different combined statuses of frailty and polypharmacy on risks of adverse outcomes. The subjects were aged 65-100 years old and were identified from an Insurance Research Database in Taiwan. Frailty was categorized into fit, mild, moderate, and severe frailty based on the multimorbidity frailty index. The use of 5-9 and over …

Osteoporosis Treatment Beyond 5 Years

Angie Szumlinski Health, Studies

For more than 2 decades, bisphosphonate drugs have been a first-line therapy for preventing osteoporotic fractures, based on strong clinical evidence showing significant fracture risk reduction within the first 3 to 5 years of treatment. However, data regarding the optimal duration of bisphosphonate treatment to minimize fracture risk beyond this initial period of time are limited. In September 2015, a …